Literature DB >> 30637465

RSV hospitalization in infancy increases the risk of current wheeze at age 6 in late preterm born children without atopic predisposition.

Koos Korsten1, Maarten O Blanken1, Brigitte J M Buiteman1, Elisabeth E Nibbelke1, Christiana A Naaktgeboren2, Louis J Bont1,3, Joanne G Wildenbeest4.   

Abstract

Severe respiratory syncytial virus (RSV) infection during infancy is associated with ongoing respiratory morbidity. In a large birth cohort of 2210 healthy preterm infants born at 32-35 weeks of gestation, we aimed to determine the role of atopy in the link between RSV hospitalization and current wheeze at age 6. We defined current wheeze as parent-reported wheeze or the use of respiratory medication in the past 12 months. Based on a positive family history of atopic disease, we distinguished between children with and without atopic predisposition. Six-year follow-up data was obtained in 997/1559 (64%) children of which 102 (10.2%) children had been hospitalized with RSV during infancy. Current wheeze was present in 184/997 (18.6%) children. RSV hospitalization was an independent risk factor for current wheeze in children without atopic predisposition (aOR 4.05 [95% CI 1.22-12.52]) but not in children with this atopic background (aOR 1.50 [95% CI 0.81-2.71]).
Conclusion: This is the largest published birth cohort demonstrating that in late preterm infants, atopic predisposition defines the relationship between RSV hospitalization and current wheeze. Future RSV prevention trials aiming to prevent ongoing respiratory symptoms should be analyzed separately for atopic status. What is Known: • RSV infection is responsible for a significant burden of disease in young children worldwide. • Severe RSV infection in early life is associated with asthmatic symptoms later in life. What is New: • This is the largest published birth cohort reporting about the role of atopic predisposition in the link between severe RSV infection and current wheeze at school age. • We show that RSV hospitalization in infancy is an independent risk factor for current wheeze in late preterm children without atopic predisposition at age 6. This was not seen in children with atopic predisposition.

Entities:  

Keywords:  Atopy; Preterm; RSV; Respiratory syncytial virus; Wheeze

Mesh:

Year:  2019        PMID: 30637465     DOI: 10.1007/s00431-018-03309-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  6 in total

Review 1.  Immunopathology of RSV: An Updated Review.

Authors:  Harrison C Bergeron; Ralph A Tripp
Journal:  Viruses       Date:  2021-12-10       Impact factor: 5.048

2.  Impact of Respiratory Syncytial Virus on Child, Caregiver, and Family Quality of Life in the United States: Systematic Literature Review and Analysis.

Authors:  Elizabeth L Glaser; Dhwani Hariharan; Diana M Bowser; Raíssa M Gervasio; Katharine R Rowlands; Lauren Buckley; Christopher B Nelson; Donald S Shepard
Journal:  J Infect Dis       Date:  2022-08-15       Impact factor: 7.759

Review 3.  T cells in severe childhood asthma.

Authors:  Alberta G A Paul; Lyndsey M Muehling; Jacob D Eccles; Judith A Woodfolk
Journal:  Clin Exp Allergy       Date:  2019-04-04       Impact factor: 5.018

4.  Clinical features and radiographic findings in cats with eosinophilic, neutrophilic, and mixed airway inflammation (2011-2018).

Authors:  Elizabeth A Lee; Lynelle R Johnson; Eric G Johnson; William Vernau
Journal:  J Vet Intern Med       Date:  2020-04-27       Impact factor: 3.333

Review 5.  Respiratory Follow Up of the Premature Neonates-Rationale and Practical Issues.

Authors:  Raluca Daniela Bogdan; Roxana Elena Bohiltea; Adrian Ioan Toma
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

6.  Early-life respiratory syncytial virus lower respiratory tract infection in a South African birth cohort: epidemiology and effect on lung health.

Authors:  Heather J Zar; Polite Nduru; Jacob A M Stadler; Diane Gray; Whitney Barnett; Maia Lesosky; Landon Myer; Mark P Nicol
Journal:  Lancet Glob Health       Date:  2020-10       Impact factor: 38.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.